|
|
|
24.03.26 - 21:48
|
XFRA: Deletion of Instruments from Boerse Frankfurt - 24.03.2026 (XETRA)
|
|
|
The following instruments on Boerse Frankfurt do have their last trading day on 24.03.2026.
Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.03.2026.
ISIN Name
CA4013392051 GUARDIAN CAPITAL GRP
CA4013393042 GUARDIAN CAP. GRP A
FR0010907956 CARMAT EO -,04
LU0934195610 ROB.GL.T.R.BD F.DH EO
NO0013671115 INTL PETROL 25/30
US30063P1057 EXACT SCIEN. DL-,01
US5834352016 STEAKHOLDER F.NEW ADR/100
US68237Q2030 ONCONETIX INC.
US98386D3070 XTL BIOPHARMA. ADR 100
XS3307259237 IBERDROLA FINANZAS S.A....
|
|
|
24.03.26 - 16:42
|
XFRA: ISIN Change (XETRA)
|
|
|
Einstellung Aufnahme
ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen
US68237Q2030 Onconetix Inc. 24.03.2026 US68237Q3020 Onconetix Inc. 25.03.2026 Tausch 5:1
US98386D3070 XTL Biopharmaceuticals Ltd. 24.03.2026 US98386D4060 XTL Biopharmaceuticals Ltd. 25.03.2026 Tausch 4:1...
|
|
|
|
|
20.03.26 - 21:12
|
XTL Biopharmaceuticals Announces ADS Ratio Change (GlobeNewswire EN)
|
|
|
RAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares, par value NIS0.1 per share (the "ADS Ratio"), from the current ADS Ratio of one (1) ADS to one hundred (100) ordinary shares, to a new ADS Ratio of one (1) ADS to four hundred (400) ordinary shares (the "ADS Ratio Change"). The Company anticipates that the ADS Ratio Change will be effective on March 25, 2026 (the "Effective Date")....
|
|
|
|
|
|
|
|
|
27.02.26 - 22:33
|
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing (GlobeNewswire EN)
|
|
|
RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a “public shell”, and that continued listing of the Company's American Depositary Shares (“ADSs”) is no longer warranted. The Company intends to request a hearing (the “Hearing”) to appeal the delisting process before a Nasdaq Hearings Panel (the “Panel”). A Hearing request will stay the suspension of the ADSs and delisting pending the Panel's decision....
|
|
|
29.01.26 - 22:09
|
XTL Update on Recent Developments (GlobeNewswire EN)
|
|
|
RAMAT GAN, ISRAEL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced that it is working diligently to close the acquisition of 85% of the shares of NeuroNOS Ltd. from Beyond Air Inc, following the execution of the Binding Letter of Intent on January 13 , 2026 (as disclosed in the Company's Report of Foreign Private Issuer on Form 6-K filed on January 13, 2026), and has already scheduled a shareholders meeting for February 17, 2026 to approve a private placement of up to US$2 million....
|
|
|
23.01.26 - 22:12
|
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders′ Equity Deficiency (GlobeNewswire EN)
|
|
|
RAMAT GAN, ISRAEL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated January 20, 2026, notifying the Company that the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(b)(1), to maintain a minimum of $2,500,000 in stockholders' equity for continued listing. This Nasdaq determination was based on (i) the Company's Form 6-K, dated December 30, 2025, that included financial information for the period ended June 30, 2025, and which reported stockholders' equity deficit of $47,000, and (ii) that the Company does not meet the alternatives of market value of listed securities or net income from continuing operations as of January 20, 2026....
|
|
|
|
|
|
|
|
|
24.12.25 - 22:03
|
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency (GlobeNewswire EN)
|
|
|
RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated December 22, 2025, notifying the Company that based on XTL's closing bid price for the last 30 consecutive business days, the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
